Citadel Advisors’s DNA X Inc SONM Stock Holding History

Citadel Advisors’s Portfolio SONM Stock Details SONM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.1K	Buy	+12,740	New	+$56.5K	﹤0.01%	12986
2021 Q3	–	Sell	-35	Closed	-$35K	–	14591
2021 Q2	$35K	Buy	35 +24	+218%	+$26.1K	﹤0.01%	13451
2021 Q1	$17K	Buy	+11	New	+$19.4K	﹤0.01%	13077

Other funds holding SONM

CWM

C2C Wealth Management Scottsdale, Arizona $128M AUM 22.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citadel Advisors's SONM Position: Q2 2026 in Review

Citadel Advisors opened a new position in DNA X Inc (SONM) in Q2 2026: 12,740 shares worth $65.1K. The stake represents ﹤0.01% of the portfolio and ranks #12986 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SONM as recently as Q2 2021.

Citadel Advisors first reported a position in SONM in Q1 2021 and has held it in 3 quarters since. 9 funds tracked by Wall St. Rank hold SONM as of Q2 2026.

Citadel Advisors held 12,740 shares of DNA X Inc worth $65.1K as of Q2 2026.
DNA X Inc was a new Citadel Advisors position in Q2 2026.
DNA X Inc made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12986 holding.
Citadel Advisors first reported a position in DNA X Inc in Q1 2021 and has held it in 3 quarters since.
9 funds tracked by Wall St. Rank held DNA X Inc as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.